The demonstrated capabilities of this magnetoimmunosensing platform for ERα quantitation in spiked human serum and cell lysates with no matrix effect, as well to assess ERα in intact breast cancer cells, make it competitive in terms of simplicity, rapidity and reliability, with conventional strategies applied in clinical practice for diagnosis, monitoring and follow-up of metastatic breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.